FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell‐Induced Severe or Life‐Threatening Cytokine Release Syndrome

On August 30, 2017, the U.S. Food and Drug Administration approved Actemra (tocilizumab, Genentech, Inc., South San Francisco, CA) for the treatment of severe or life‐threatening chimeric antigen receptor (CAR) T cell‐induced cytokine release syndrome (CRS) in adults and in pediatric patients 2 year...

Descripción completa

Detalles Bibliográficos
Autores principales: Le, Robert Q., Li, Liang, Yuan, Weishi, Shord, Stacy S., Nie, Lei, Habtemariam, Bahru A., Przepiorka, Donna, Farrell, Ann T., Pazdur, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2018
Materias:
Regulatory Issues: FDA
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6156173/
https://www.ncbi.nlm.nih.gov/pubmed/29622697
http://dx.doi.org/10.1634/theoncologist.2018-0028

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6156173/
https://www.ncbi.nlm.nih.gov/pubmed/29622697
http://dx.doi.org/10.1634/theoncologist.2018-0028

Ejemplares similares